These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16583669)

  • 21. "Short- and long-term mortality with localized prostate cancer": errors and omissions?
    Roach M
    Arch Intern Med; 2008 Jun; 168(12):1351; author reply 1353. PubMed ID: 18574095
    [No Abstract]   [Full Text] [Related]  

  • 22. [Observational survey on variations of prostate cancer incidence by stage in the Nord-Pas-de-Calais region between 1998 and 2004].
    Flamand V; Zini L; Salleron J; Fantoni JC; Biserte J; Villers A
    Prog Urol; 2008 Jan; 18(1):53-9. PubMed ID: 18342157
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 24. Higher frequency of familial clustering of prostate cancer in French-Canadian men.
    Filion E; Taussky D; Bahary JP; Maugard CM
    J Urol; 2007 Oct; 178(4 Pt 1):1265-9; discussion 1270. PubMed ID: 17698103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS; Tesoro R; Elkin EP; Sadetsky N; Broering JM; Latini DM; DuChane J; Mody RR; Carroll PR
    Cancer; 2007 Feb; 109(3):518-27. PubMed ID: 17186528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities.
    Eggener SE; Scardino PT; Carroll PR; Zelefsky MJ; Sartor O; Hricak H; Wheeler TM; Fine SW; Trachtenberg J; Rubin MA; Ohori M; Kuroiwa K; Rossignol M; Abenhaim L;
    J Urol; 2007 Dec; 178(6):2260-7. PubMed ID: 17936815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results.
    Maestroni U; Ziveri M; Azzolini N; Dinale F; Ziglioli F; Campaniello G; Frattini A; Ferretti S
    Acta Biomed; 2008 Dec; 79(3):211-6. PubMed ID: 19260381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Albertson PC
    Eur Urol; 2009 Jun; 55(6):1331-2. PubMed ID: 19286304
    [No Abstract]   [Full Text] [Related]  

  • 29. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. When watchful waiting is right choice for prostate cancer.
    Johns Hopkins Med Lett Health After 50; 2006 Oct; 18(8):1-2. PubMed ID: 17146873
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Joniau S
    Eur Urol; 2008 Feb; 53(2):362. PubMed ID: 17611018
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment on: predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Scattoni V
    Eur Urol; 2008 Feb; 53(2):361. PubMed ID: 17611014
    [No Abstract]   [Full Text] [Related]  

  • 33. Secondary cancer and relapse rates following radical prostatectomy for prostate-confined cancer.
    Wesley D; Cox HF
    J Insur Med; 2007; 39(4):242-50. PubMed ID: 18522141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The management of category T1a-T1b (incidental) prostate cancer: can we predict who needs treatment?
    Adolfsson J
    Eur Urol; 2008 Jul; 54(1):16-8. PubMed ID: 18406047
    [No Abstract]   [Full Text] [Related]  

  • 35. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer mortality in Rhode Island cities and towns, 1987-2000.
    Fulton JP; Chiaverini L
    Med Health R I; 2003 Oct; 86(10):329-31. PubMed ID: 14626867
    [No Abstract]   [Full Text] [Related]  

  • 37. Rhode Island Hispanics have mainstream cancer rates.
    Fulton JP; Buechner JS
    Med Health R I; 2002 Jan; 85(1):32-3. PubMed ID: 11824154
    [No Abstract]   [Full Text] [Related]  

  • 38. Early detection the key to prostate cancer.
    Kirby R
    Practitioner; 2009 Feb; 253(1715):17-8, 21-2. PubMed ID: 19326658
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical study of stage a prostatic cancer detected incidentally by transurethral resection of the prostate].
    Nakanishi S; Gotou T; Sawada A; Shibasaki N; Ishitoya T; Okumura K
    Hinyokika Kiyo; 2009 Jan; 55(1):5-8. PubMed ID: 19227204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reassessing cancer mortality in Rhode Island, an old urban state.
    Chiaverini L; Fulton JP
    Med Health R I; 2002 Aug; 85(8):256-7. PubMed ID: 12216349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.